ADC Therapeutics S.A.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ADC Therapeutics SA (ADCT) develops and commercializes antibody drug conjugates (ADCs) for the treatment of hematologic malignancies and solid tumors. The company markets ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC approved by the U.S. FDA, the European Commission and China's National Medical Products Administration for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior lines of systemic therapy; it advances ZYNLONTA expansions into earlier lines of DLBCL and indolent lymphomas such as follicular lymphoma and marginal zone lymphoma through the LOTIS-5 Phase 3 confirmatory trial, LOTIS-7 Phase 1b trial in combination with glofitamab, and investigator-initiated trials. Its early-stage pipeline features ADCT-241, an exatecan-based PSMA-targeting ADC in IND-enabling studies for prostate cancer, leveraging proprietary pyrrolobenzodiazepine (PBD) technology and novel hydrophilic linkers. Founded in 2011 and headquartered in Epalinges, Switzerland, ADC Therapeutics operates primarily in the U.S. and Europe with maximum revenue from the United States. In June 2025, the company completed a $100 million private placement financing of common shares and pre-funded warrants to extend its cash runway into 2028 and support ZYNLONTA catalysts alongside PSMA program advancement while discontinuing other preclinical solid tumor efforts; it recently granted inducement equity awards to new employees under its plan.
Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
First Look: JPM risks, XWEL deal, UAL fares, SpaceX halo
ADC Therapeutics Announces New Employee Inducement Grant
ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Strategy, Clinical Progress, and Sales Growth Outlook Transcript
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics to Participate in March Investor Conferences
ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement